Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Plasmablastic Lymphoma 1 Lymphomatoid Granulomatosis 1 Lymphoma, Primary Effusion 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Glioblastoma 1 Burkitt Lymphoma 1

Interventions

Temozolomide 18 Radiotherapy 11 Magnetic Resonance Spectroscopy 11 Specimen Handling 8 Radiation 7 Lomustine 4 Nivolumab 3 Biopsy 3 trametinib 2 rocakinogene sifuplasmid 2 dabrafenib 2 cemiplimab 2 Receptors, Interleukin-8B 2 Photons 2 Palliative Care 2 Ipilimumab 2 CTLA-4 Antigen 2 vocimagene amiretrorepvec 1 veliparib 1 varlilumab 1 tinostamustine 1 temsirolimus 1 senicapoc 1 selinexor 1 relatlimab 1 regorafenib 1 perampanel 1 peposertib 1 pembrolizumab 1 pazopanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × varlilumab × 30 days × Clear all

NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡